Vitamin D (vit-D) deficiency is common in patients with gastro-entero-pancreatic neuroendocrine tumours (GEP-NET) and has been linked to reduced survival in these patients. Vit-D status was assessed in 183 patients with GEP-NET, at the time of their first presentation in the ARDEN-NET-Centre; and following simple advice at routine 6-monthly follow-up appointments to increase vit-D intake using over-the-counter vit-D preparations (Colecalciferol (Vit-D3), 10002000 units/day), over a prospective observation period of 24-months. At baseline, 67% of the patients were either vit-D insufficient (31%; 25-OH-vit- D 2550 nmol/l) or deficient (36%; 25-OH-vit-D<25 nmol/l). 25-OH-vit-D significantly increased from 38±4 nmol/l at baseline to 60±6 nmol/l (P<0.0001) and 57±7 nmol/l (P=0.039) after 12 and 24-months, respectively. Percentage of vit-D insufficiency decreased from 66.6% at baseline to 44.9 and 46.2% after 12 and 24 months, respectively. Previous abdominal surgery was the only significant predictor of serum 25-OH-vit-D concentrations in bootstrapped linear regression analyses (P=0.037). In summary: simple advice to increase vit-D intake using over-the-counter preparations significantly improved highly prevalent vit-D deficiency/insufficiency in GEP-NET patients; although, 15% of patients remained deficient and should be considered for additional measures of vit-D replacement.
04 Dec 2017
UK and Ireland Neuroendocrine Tumour Society